CERTCertara, Inc.

Nasdaq certara.com


$ 16.93 $ -0.06 (-0.35 %)    

Friday, 10-May-2024 15:59:56 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 17
$ 17.16
$ 0.00 x 0
$ 0.00 x 0
$ 16.60 - $ 17.25
$ 11.81 - $ 22.65
437,091
na
2.71B
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 certara-q1-2024-gaap-eps-010-inline-sales-96654m-beat-93637m-estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. The company rep...

 keybanc-upgrades-certara-to-overweight-announces-23-price-target

Keybanc analyst Scott Schoenhaus upgrades Certara (NASDAQ:CERT) from Sector Weight to Overweight and announces $23 price tar...

 jmp-securities-initiates-coverage-on-certara-with-market-perform-rating

JMP Securities analyst Constantine Davides initiates coverage on Certara (NASDAQ:CERT) with a Market Perform rating.

 ubs-maintains-neutral-on-certara-raises-price-target-to-20

UBS analyst Dan Leonard maintains Certara (NASDAQ:CERT) with a Neutral and raises the price target from $17 to $20.

 jefferies-maintains-hold-on-certara-raises-price-target-to-155

Jefferies analyst David Windley maintains Certara (NASDAQ:CERT) with a Hold and raises the price target from $14 to $15.5.

 certara-q4-2023-adj-eps-0090-misses-0110-estimate-sales-88m-beat-86596m-estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.090 per share which missed the analyst consensus estimate of $0.110 by ...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 leerink-partners-initiates-coverage-on-certara-with-market-perform-rating-announces-price-target-of-19

Leerink Partners analyst Michael Cherny initiates coverage on Certara (NASDAQ:CERT) with a Market Perform rating and announc...

 tax-season-is-here-meet-the-new-federal-program-that-can-eat-away-at-tax-preparation-companies

New IRS program launching for free tax filing could affect tax prep companies like H&R Block and Intuit. Market share drop ...

 barclays-maintains-equal-weight-on-certara-raises-price-target-to-18

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $16 to $18.

 ubs-initiates-coverage-on-certara-with-neutral-rating-announces-price-target-of-17

UBS analyst Dan Leonard initiates coverage on Certara (NASDAQ:CERT) with a Neutral rating and announces Price Target of $17.

 keybanc-initiates-coverage-on-certara-with-sector-weight-rating

Keybanc analyst Scott Schoenhaus initiates coverage on Certara (NASDAQ:CERT) with a Sector Weight rating.

 certara-introduces-simcyp-biopharmaceutics-software-to-increase-efficiency-of-novel-and-generic-drug-formulation--development

Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics sof...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION